Benzinga

APRIL 11, 2024

Thursday, Century Therapeutics (NASDAQ: IPSC ) unveiled plans to expand clinical development for its lead program, CNTY-101, a CD19-targeting iNK cell therapy, into additional autoimmune disease indications.

Finance 59

Finance 59

Benzinga

APRIL 11, 2024

The analyst notes it as a solid acquisition and aligned with Vertex’s emerging footprint in nephrology following the advancement of inaxaplin in APOL1-mediated kidney disease and early-stage candidate VX-407 for autosomal dominant polycystic kidney disease. billion before the acquisition.

Equity 59

Equity 59

Benzinga

APRIL 16, 2024

Analyst Cory A. On Monday, Snap One announced it will be acquired by Resideo Technologies for $1.4 billion in cash. We covered the news first here: Why Is Snap One Stock Jumping Premarket Monday? Carpenter from JPMorgan provided valuable insights on the acquisition, calling it a “strong strategic fit at reasonable value.”

Technology 52

Technology Marketability 52

Benzinga

SEPTEMBER 10, 2023

Cannabis industry analyst Pablo Zuanic , from Z&A, is set to take the stage as a featured speaker at the highly anticipated Benzinga Cannabis Capital Conference in Chicago, scheduled for September 27-28. companies to tap into the $28 billion U.S.

Marketability 105

Marketability 105

Benzinga

APRIL 8, 2024

Johnson & Johnson (NYSE: JNJ ) agreed on Friday to acquire Shockwave Medical Inc (NASDAQ: SWAV ) for $335 per share in cash, corresponding to an enterprise value of approximately $13.1 billion, including cash acquired.

Enterprise Value 52

Enterprise Value Marketability 52

Benzinga

MARCH 27, 2024

The Royal Gold Analyst: BMO Capital's Jackie Przybylowski upgraded the rating for the Denver-based company from Market Perform to Outperform, while raising the price target from $148 to $158.

Dividends 52

Dividends Marketability 52

Benzinga

JANUARY 16, 2024

Amidst potential shifts in U.S. cannabis regulation, Lance Boldrey , leader of Cannabis Law Practice at Dykema Gossett PLLC , analyzes the potential impact of reclassifying cannabis to Schedule III under the Controlled Substance Act.

Marketability 69

Marketability 69

Benzinga

JUNE 26, 2023

See Also: Manchester United Attracts Record Takeover Bid Earnings Preview : For the third-quarter (Q3), analysts predict: Losses per share of £0.04 (US$0.05) compared to losses of £0.138 per share over the same three-month period last year. "I'm genuinely not sure what the hold up is here," the source added.

98

98

Benzinga

DECEMBER 27, 2023

With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) is potentially the sole remaining clinical-stage player with a robust supply chain.

Alpha 69

Alpha Equity 69

Benzinga

JULY 9, 2022

Wedbush analyst Daniel Ives said he sees a "long, nasty court battle" ahead. Legal Battle In Cards: Close on the heels of Musk's disclosure of his intentions, Bret Taylor, chairman of Twitter's board, tweeted that the board is committed to closing the transaction on the price and terms agreed upon with Musk.

Start-ups 131

Start-ups 131

Benzinga

FEBRUARY 29, 2024

Privately held CoreRx Inc. will acquire Societal CDMO Inc (NASDAQ: SCTL ), a contract development and manufacturing organization. CoreRx on Wednesday said it will commence a tender offer to acquire all outstanding shares of Societal CDMO for $1.10 per share in cash.

Equity 52

Equity Marketability 52

Benzinga

JANUARY 29, 2024

Equity and M&A experts believe that, after a year beset by volatile markets and rising interest rates, 2024 offers improving conditions for takeover deals and corporate mergers. Pitchbook analyst Tim Clarke noted how higher interest rates made it more costly for PE firms to engage in deals. trillion in 2023, down from $3.1

Equity 59

Equity Marketability Finance 59

Benzinga

FEBRUARY 28, 2024

Gone — at least for the medium term — is the era of low interest rates and the days of highly leveraged deals. Higher interest rates. As rates moved higher, access to cheap funding to finance PE deals was more scarce, which caused activity in the mergers and acquisitions. The private equity environment has changed.

Equity 52

Equity Banking Finance Marketability 52

Benzinga

APRIL 11, 2023

Related: Value-Adding Vision: Analysts Dismiss Glencore’s Deal as Teck Resources’ Proposed Plan Gains Favor. The revised proposal does not increase the overall value to be received by Teck shareholders or appears to address material risks previously raised by Teck.

Banking 98

Banking Marketability 98

Benzinga

FEBRUARY 23, 2024

The Zoom Video Analyst: JPMorgan analyst Mark R. Murphy rates the stock Neutral with a price target of $83. It is set to report fourth-quarter earnings on Feb. 26 (after market hours), with the Street expecting $1.15 in EPS and $1.11 billion in revenue. This implies an upside of 33.69% from a price of $62.12

Marketability 52

Marketability 52

Benzinga

FEBRUARY 21, 2024

Shares of VIZIO Holding (NYSE: VZIO ) closed lower on Wednesday amid a series of downgrades from Wall Street analysts. A review of ratings and analysis (both fundamental and technical) by Benzinga also indicates Vizio to be a very unpromising asset. JPMorgan downgraded the stock to Neutral, while raising their price target to $11.50

52

52

Benzinga

MARCH 20, 2023

On Monday, one analyst said the Credit Suisse acquisition makes UBS an attractive investment. The UBS Analyst: Bank of America analyst Alastair Ryan upgraded UBS from Neutral to Buy and raised the price target from $22.72

Banking 97

Banking 97

Benzinga

MARCH 9, 2023

UBS analyst Manav Gupta initiated coverage of Marathon Petroleum Corp (NYSE: MPC ) with a Buy rating and price target of $165. Gupta's report comes on the heels of Marathon's acquiring a 49.9% stake in renewable natural gas producer LF Bioenergy for $50 million. Over the past couple of years, the company has paid out $19.3

97

97

Benzinga

FEBRUARY 9, 2023

Wedbush analyst Michael Pachter laid out why the regulatory chatter is really just noise and explained why he expects the deal to go through on Benzinga's PreMarket Prep show.

Marketability 98

Marketability 98

Benzinga

JANUARY 9, 2023

Steve Hanke , a professor of Applied Economics at Johns Hopkins University , has criticized the Federal Reserve’s monetary policy and President Joe Biden’s administration for a sharp drop in deal activity last year.

Finance 98

Finance 98

Benzinga

FEBRUARY 13, 2024

Monday, Gilead Sciences Inc (NASDAQ: GILD ) agreed to acquire CymaBay Therapeutics Inc (NASDAQ: CBAY ) for $32.50 per share in cash or a total equity value of $4.3

Equity 52

Equity 52

Benzinga

NOVEMBER 29, 2022

The analyst retained an "Overweight" rating on the company's stock while keeping his price target of $15. Cantor Fitzgerald's Pablo Zuanic has crunched Q3 earnings numbers for two cannabis MSOs following Auxly Cannabis Group Inc. 's 's (TSX: XLY) (OTCQX: CBWTF ) and Columbia Care Inc. 's

Marketability 98

Marketability 98

Benzinga

DECEMBER 20, 2022

JMP has raised the price target from $182 to $312 and reiterates its Market Outperform rating. Resmetirom looks approvable based on Phase 3 MAESTRO-NASH data, the analyst said. The analyst raised POS for resmetirom to 90% in both the U.S. and EU (from 70% and 60%, respectively) with peak sales of ~$5 billion and ~$1.5

Marketability 98

Marketability 98

Benzinga

JANUARY 23, 2024

The penetration rates for the PE and DVT markets are approximately 20% and 15%, respectively. Needham initiates with a Buy rating and a price target of $72. Additionally, the company estimates a yearly count of 430,000 patients with deep vein thrombosis (DVT), resulting in a $3.0 billion TAM for its ClotTriever product.

Marketability 52

Marketability Equity 52

Benzinga

JANUARY 22, 2024

The Comerica Analyst: Michael Rose downgraded the rating for Comerica from Outperform to Market Perform. The company faces nearer-term earnings challenges, which put into question its ability to “generate positive operating leverage into 2025,” according to Raymond James.

Marketability 52

Marketability 52

Benzinga

DECEMBER 4, 2023

The ImmunoGen Analyst : Joseph Catanzaro downgraded the rating for ImmunoGen from Overweight to Neutral, while raising the price target from $24 to $31. Check out other analyst stock ratings. The deal, which is expected to close in mid-2024, represents a “great price” for ImmunoGen, at $31.26

59

59

Benzinga

JANUARY 18, 2024

The Tempur Sealy International Analyst: Peter Keith upgraded the rating for Tempur Sealy International from Neutral to Overweight, while raising the price target from $41 to $61. The Tempur Sealy International Thesis: The company is likely to.

52

52

Benzinga

NOVEMBER 18, 2022

Thursday after close, Evolent Health Inc (NYSE: EVH ) agreed to acquire Magellan Specialty Health, the specialty benefit management organization owned by Centene Corporation (NYSE: CNC ), for $650 million at the close plus additional contingent consideration of up to $150 million based on 2023 performance.

98

98

Benzinga

JANUARY 9, 2024

“It’s a gamers world — more than four in 10 people globally are gamers,” said Brian Pitz , internet and interactive entertainment analyst at BMO Capital Markets. Audience growth, the analyst said, has continued uninterrupted since the early 2000s and is forecast to reach 3.8 billion gamers by 2026.

Marketability 52

Marketability Equity 52

Benzinga

OCTOBER 19, 2022

The Analyst: Lawson Winder upgraded the rating for Iamgold from. The deal represents a significant move in addressing the funding gap for the development of the Côté Gold mine, according to Bank of America Securities. Full story available on Benzinga.com.

Banking 98

Banking 98

Benzinga

OCTOBER 9, 2022

Tesla, Inc. NASDAQ: TSLA ) shares came under significant selling pressure this week, with CEO Elon Musk’s announcement to revive the Twitter, Inc. NYSE: TWTR ) deal partly to blame for the predicament. Longtime Tesla bull and Loup Funds’ Gene Munster offered his take on three key questions surrounding the deal.

Finance 98

Finance 98

Benzinga

OCTOBER 7, 2022

What Happened: Delving on the development, Future Fund analyst Gary Black suggested the deferral was to Musk's advantage. Financial companies, including big Wall Street banks, are under pressure amid market uncertainties precipitated by a rising rate environment. NASDAQ: TSLA ) reports its earnings on Oct.

Debt Financing 98

Debt Financing Banking Finance Marketability 98

Benzinga

OCTOBER 6, 2022

An analyst is using a food analogy to describe the potential of the world’s richest man needing help to finance his acquisition by selling shares of leading electric vehicle company Tesla Inc (NASDAQ: TSLA ). The acquisition is at the original price set earlier this year by Musk before he walked away from the deal.

Finance 98

Finance 98

Benzinga

OCTOBER 6, 2022

Tesla shares will likely continue to underperform as long as Musk is tightlipped about whether he has to sell more shares to finance the Twitter deal, Future Fund analyst Gary Black said. The analyst said. See Also: As Musk Comes Around, Carl Icahn And These Fund Managers Could Be In For A Windfall From Twitter Deal.

Finance 98

Finance 98

Benzinga

OCTOBER 5, 2022

The Twitter Ananlyst: To give effect to the development, Wedbush analyst Daniel Ives raised his price target for the Twitter stock from $50 to $54.20. The analyst maintained his Neutral rating on the shares. (NASDAQ: TWTR ) for the originally agreed price of $44 billion. The Twitter Thesis: Tesla Inc.

98

98

Benzinga

OCTOBER 21, 2022

The Analyst: Michael Feniger upgraded the rating for GFL Environmental from Neutral to Buy, while reducing the price target from $34. Full story available on Benzinga.com.

97

97

Benzinga

SEPTEMBER 2, 2022

On Thursday, analyst Pablo Zuanic from Cantor Fitzgerald offered an industry update on four recent M&A deals and Glasshouse Series B Preferred stock issuance. Highlights. Zuanic said the deal between Curaleaf Holdings Inc.

Dividends 98

Dividends Marketability 98